Boston Scientific Corporation (BSX) Financial Results Summary

2026-02-04 · Stocks · QuoteReporter

Boston Scientific (BSX) Q4 2025 Financial Results Summary

Release Date: February 4, 2026

Boston Scientific Corporation (NYSE: BSX) announced its fourth quarter and full year 2025 financial results, showcasing strong growth in sales and profitability compared to the previous year. The highlights are detailed below:

Fourth Quarter Highlights

Net Sales:
Reported net sales of $5.286 billion, up 15.9% on a reported basis, 14.3% operationally, and 12.7% organically compared to the same quarter last year.
Sales forecast was between 14.5% to 16.5% (reported) and 11% to 13% (organic).
Income:
GAAP net income attributable to common stockholders reached $672 million or $0.45 per share compared to $566 million or $0.38 per share from the previous year’s quarter.
Adjusted EPS for the quarter was $0.80, an increase from $0.70 a year ago.
Segment Performance:
MedSurg:
- Net sales growth of 11.7% reported; 10.2% operational; 6.5% organic.
Cardiovascular:
- Net sales growth of 18.2% reported; 16.5% operational; 16.1% organic.
Geographical Performance:
United States: 17.0% growth reported and operational.
EMEA: 12.4% growth reported; 4.8% operational.
Asia-Pacific: 15.2% growth reported; 14.8% operational.
Latin America and Canada: 15.9% growth reported; 10.4% operational.
Emerging Markets: 15.4% reported; 13.0% operational.

Full Year Highlights

Net Sales:
Totaled $20.074 billion, representing growth of 19.9% on a reported basis, 19.2% on an operational basis, and 15.8% on an organic basis compared to 2024.
Income:
GAAP net income reached $2.898 billion or $1.94 per share, compared to $1.853 billion or $1.25 per share in the previous year.
Full year adjusted EPS was $3.06, up from $2.51 year-over-year.

Recent Developments

Product Approvals and Trials:
Received FDA approval and CE mark for the FARAPOINT™ Pulsed Field Ablation Catheter.
Enrolled patients in the OPTIMIZE and SIMPLAAFY clinical trials focusing on new heart procedures.
Launched the SEISMIQ™ Intravascular Lithotripsy System in the U.S.
Acquisitions:
Announced acquisition agreements for Penumbra, Inc. and Valencia Technologies Corporation.
Completed acquisition of Nalu Medical, Inc..

Dividends and Share Repurchase

The company did not disclose any quarterly dividends or share repurchase plans in the announcement.

Guidance for Full Year and First Quarter 2026

The company estimates net sales growth for 2026 to be approximately 10.5% to 11.5% on a reported basis and 10.0% to 11.0% on an organic basis.
Adjusted EPS guidance for 2026 is projected between $3.43 and $3.49.
For Q1 2026, net sales growth is expected to be 10.5% to 12.0% on a reported basis and 8.5% to 10.0% on an organic basis, with an adjusted EPS of approximately $0.78 to $0.80.

Conclusion

Boston Scientific’s fourth quarter and full-year results reflect a solid performance with substantial growth across various segments and geographies, positioning the company favorably for continued success in the future.

BOSTON SCIENTIFIC CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in millions)

Three Months Ended	December 31, 2025	December 31, 2024	Year Ended	December 31, 2025
Net sales	$ 5,286	$ 4,561	$ 20,074	$ 16,747
Cost of products sold (excluding amortization expense)	1,608	1,466	6,221	5,257
Gross profit	3,678	3,095	13,854	11,490
Operating expenses:
Selling, general and administrative expenses	1,834	1,612	6,887	5,984
Research and development expenses	569	460	2,052	1,615
Royalty expense	6	10	46	33
Amortization expense	228	225	897	856
Intangible asset impairment charges	—	111	46	386
Contingent consideration net expense (benefit)	6	-1	18	-5
Restructuring net charges (credits)	16	4	101	16
Litigation-related net charges (credits)	194	—	194	—
Operating income (loss)	825	675	3,613	2,603
Other income (expense):
Interest expense	-90	-80	-349	-305
Other, net	-34	-10	121	-16
Income (loss) before income taxes	700	585	3,385	2,282
Income tax expense (benefit)	30	23	493	436
Net income (loss)	$ 670	$ 562	$ 2,892	$ 1,846
Net income (loss) attributable to noncontrolling interests	-2	-4	-6	-8
Net income (loss) attributable to Boston Scientific common stockholders	$ 672	$ 566	$ 2,898	$ 1,853
Net income (loss) per common share – basic	0.45	0.38	1.96	1.26
Net income (loss) per common share – diluted	0.45	0.38	1.94	1.25
Weighted-average shares outstanding
Basic	1,482.7	1,474.2	1,480.4	1,471.5
Diluted	1,495.8	1,490.2	1,494.5	1,485.9
Amounts may not add due to rounding

BOSTON SCIENTIFIC CORPORATION CONSOLIDATED BALANCE SHEETS

(Unaudited, in millions)

December 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	xxxxx	xxxxx
Accounts receivable	xxxxx	xxxxx
Inventory	xxxxx	xxxxx
Other current assets	xxxxx	xxxxx
Total current assets	xxxxx	xxxxx
Property, plant and equipment, net	xxxxx	xxxxx
Goodwill and intangible assets	xxxxx	xxxxx
Other assets	xxxxx	xxxxx
Total assets	$ xxxxx	$ xxxxx
Liabilities and equity
Current liabilities:
Accounts payable	xxxxx	xxxxx
Accrued liabilities	xxxxx	xxxxx
Current maturities of long-term debt	xxxxx	xxxxx
Other current liabilities	xxxxx	xxxxx
Total current liabilities	xxxxx	xxxxx
Long-term debt	xxxxx	xxxxx
Other liabilities	xxxxx	xxxxx
Total liabilities	$ xxxxx	$ xxxxx
Equity:
Common stock and additional paid-in capital	xxxxx	xxxxx
Retained earnings	xxxxx	xxxxx
Accumulated other comprehensive loss	xxxxx	xxxxx
Total equity	$ xxxxx	$ xxxxx
Total liabilities and equity	$ xxxxx	$ xxxxx

(Note: The “xxxx” values should be filled with the corresponding data from the original table.)